As he listened to dire warnings from Amgen Inc. and its well-funded allies over the safety of generic copies of expensive biotech drugs, Dr. James Liebmann said he detected another powerful motivator at work: profit.
Liebmann, a Massachusetts oncologist, is a member of a drug advisory panel of the US Food and Drug Administration. One after another, during a meeting this year, a parade of patient advocates backed by pharmaceutical companies said different generic names should be required to distinguish the cheaper versions of biotech drugs in case they cause dangerous side effects.
Hey, check out all the research scientist jobs. Post your resume today!
